Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Prepaid Assets (2017 - 2025)

Historic Prepaid Assets for Aclaris Therapeutics (ACRS) over the last 9 years, with Q2 2025 value amounting to $4.2 million.

  • Aclaris Therapeutics' Prepaid Assets fell 3241.11% to $4.2 million in Q2 2025 from the same period last year, while for Jun 2025 it was $4.2 million, marking a year-over-year decrease of 3241.11%. This contributed to the annual value of $12.0 million for FY2024, which is 2736.99% up from last year.
  • According to the latest figures from Q2 2025, Aclaris Therapeutics' Prepaid Assets is $4.2 million, which was down 3241.11% from $3.2 million recorded in Q1 2025.
  • Aclaris Therapeutics' Prepaid Assets' 5-year high stood at $19.7 million during Q3 2023, with a 5-year trough of $3.2 million in Q1 2025.
  • Over the past 5 years, Aclaris Therapeutics' median Prepaid Assets value was $9.0 million (recorded in 2021), while the average stood at $9.3 million.
  • As far as peak fluctuations go, Aclaris Therapeutics' Prepaid Assets surged by 40173.75% in 2021, and later plummeted by 7831.72% in 2024.
  • Aclaris Therapeutics' Prepaid Assets (Quarter) stood at $13.0 million in 2021, then grew by 3.85% to $13.5 million in 2022, then decreased by 29.96% to $9.5 million in 2023, then grew by 27.37% to $12.0 million in 2024, then plummeted by 65.1% to $4.2 million in 2025.
  • Its last three reported values are $4.2 million in Q2 2025, $3.2 million for Q1 2025, and $12.0 million during Q4 2024.